Candel Therapeutics, Inc.
US ˙ NasdaqGM ˙ US1374041093

Introduction

This page provides a comprehensive analysis of the known insider trading history of Paul Peter Tak. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Paul Peter Tak has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:CADL / Candel Therapeutics, Inc. Chief Executive Officer, Director 268,566
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Paul Peter Tak. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases CADL / Candel Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CADL / Candel Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2022-12-09 CADL Tak Paul Peter 12,935 1.9200 12,935 1.9200 24,835 45 2.7200 10,348 41.67
2022-12-08 CADL Tak Paul Peter 3,050 1.7000 3,050 1.7000 5,185
2021-07-29 CADL Tak Paul Peter 25,000 8.0000 25,000 8.0000 200,000

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CADL / Candel Therapeutics, Inc. Insider Trades
Insider Sales CADL / Candel Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CADL / Candel Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-01-15 CADL Tak Paul Peter 21,704 7.2250 21,704 7.2250 156,811 83 4.3950 -61,422 -39.17
2025-01-08 CADL Tak Paul Peter 21,172 8.2182 21,172 8.2182 173,996
2024-11-29 CADL Tak Paul Peter 48,847 4.5556 48,847 4.5556 222,527
2024-07-17 CADL Tak Paul Peter 22,528 6.4726 22,528 6.4726 145,815
2024-07-11 CADL Tak Paul Peter 20,293 5.9734 20,293 5.9734 121,218

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CADL / Candel Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Paul Peter Tak as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-06-26 2025-06-25 4 CADL Candel Therapeutics, Inc.
Common Stock
A - Award 42,826 268,566 18.97 4.67 199,997 1,254,203
2025-03-20 2025-03-19 4 CADL Candel Therapeutics, Inc.
Common Stock
S - Sale X -400 225,740 -0.18 9.00 -3,601 2,032,224
2025-03-20 2025-03-18 4 CADL Candel Therapeutics, Inc.
Common Stock
S - Sale X -25,772 226,140 -10.23 8.77 -226,023 1,983,270
2025-01-17 2025-01-15 4 CADL Candel Therapeutics, Inc.
Common Stock
S - Sale -21,704 251,912 -7.93 7.22 -156,811 1,820,064
2025-01-10 2025-01-08 4 CADL Candel Therapeutics, Inc.
Common Stock
S - Sale -21,172 273,616 -7.18 8.22 -173,996 2,248,631
2024-12-03 2024-11-29 4 CADL Candel Therapeutics, Inc.
Common Stock
S - Sale -48,847 294,788 -14.21 4.56 -222,527 1,342,936
2024-11-21 2024-11-21 4 CADL Candel Therapeutics, Inc.
Common Stock
M - Exercise 12,900 343,635 3.90 1.55 19,995 532,634
2024-07-19 2024-07-17 4 CADL Candel Therapeutics, Inc.
Common Stock
S - Sale -22,528 330,735 -6.38 6.47 -145,815 2,140,715
2024-07-15 2024-07-11 4 CADL Candel Therapeutics, Inc.
Common Stock
S - Sale -20,293 353,263 -5.43 5.97 -121,218 2,110,181
2023-11-30 2023-11-28 4 CADL Candel Therapeutics, Inc.
Common Stock
F - Taxes -43,443 373,556 -10.42 0.90 -39,099 336,200
2023-11-28 2023-11-26 4 CADL Candel Therapeutics, Inc.
Common Stock
A - Award 180,108 416,999 76.03
2022-12-12 2022-12-09 4 CADL Candel Therapeutics, Inc.
Common Stock
P - Purchase 12,935 40,985 46.11 1.92 24,835 78,691
2022-12-12 2022-12-08 4 CADL Candel Therapeutics, Inc.
Common Stock
P - Purchase 3,050 28,050 12.20 1.70 5,185 47,685
2022-11-30 2022-11-28 4 CADL Candel Therapeutics, Inc.
Common Stock
A - Award 195,906 220,906 783.62
2022-03-01 2022-02-28 4 CADL Candel Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 330,000 330,000
2021-08-02 2021-07-29 4 CADL Candel Therapeutics, Inc.
Common Stock
P - Purchase 25,000 25,000 8.00 200,000 200,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)